Advertisement

Cardiovascular Manifestation of Paediatric HIV Infection

  • Ebrahim GM HoosenEmail author
Chapter
  • 18 Downloads

Abstract

Prior to effective antiretroviral therapy (ART), HIV infected children demonstrated poorer ventricular function and higher ventricular masses than uninfected children. Those with the poorest myocardial function had the poorest outcomes. Effective ART improved survival as well as myocardial function. However, over time, myocardial function appears to decline. In addition, accelerated coronary artery disease, related to the effects of HIV, as well as its treatment, pose a new set of challenges as these patients approach adulthood. In untreated or inadequately treated patients, the prevalence of overt myocardial dysfunction, pericardial disease and primary as well as secondary pulmonary hypertension are significantly higher and need to be recognised and managed appropriately.

Keywords

Human immunodeficiency virus Paediatric Cardiovascular Cardiomyopathy Pericarditis Pulmonary hypertension 

References

  1. 1.
    Lipshultz SE, Easley KA, Orav EJ, et al. Cardiovascular status of infants and children of women infected with HIV-1 (P2C2 HIV): a cohort study. Lancet. 2002;360:368–73.CrossRefGoogle Scholar
  2. 2.
    Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, et al. Cardiac dysfunction and mortality in HIV-infected children: the prospective P2C2 HIV multicenter study. Pediatric pulmonary and cardiac complications of vertically transmitted HIV infection (P2C2 HIV) STUDY GROUP. Circulation. 2000;102(13):1542–8.CrossRefGoogle Scholar
  3. 3.
    Langston C, Cooper ER, Goldfarb J, Easley KA, Husak S, Sunkle S, et al. Human immunodeficiency virus-related mortality in infants and children: data from the pediatric pulmonary and cardiovascular complications of vertically transmitted HIV (P(2)C(2)) study. Pediatrics. 2001;107(2):328–38.CrossRefGoogle Scholar
  4. 4.
    Al-Attar I, Orav EJ, Exil V, Vlach SA, Lipshultz SE. Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. J Am Coll Cardiol. 2003;41:1598–605.CrossRefGoogle Scholar
  5. 5.
    Lipshultz SE, Williams PL, Wilkinson JD, Leister EC, Van Dyke RB, Shearer WT, et al. Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the adolescent master protocol of the multicenter pediatric HIV/AIDS cohort study. JAMA Pediatr. 2013;167(6):520–7.CrossRefGoogle Scholar
  6. 6.
    Lipshultz SE, Wilkinson JD, Thompson B, Cheng I, Briston DA, Shearer WT, et al. Cardiac effects of highly active antiretroviral therapy in perinatally HIV-infected children: the CART-2 study. J Am Coll Cardiol. 2017;70(18):2240–7.CrossRefGoogle Scholar
  7. 7.
    Barbaro G. HIV-associated cardiomyopathy. Herz Kardiovaskuläre Erkrankungen. 2005;30:486–92.Google Scholar
  8. 8.
    Bayrou O, Philippoteau C, Artigou C, et al. Adult Kawasaki syndrome associated with HIV infection and anti cardiolipin antibodies. J Am Acad Dermatol. 1993;29:663–4.CrossRefGoogle Scholar
  9. 9.
    Johnson RM, Little JR, Storch GA. Kawasaki like syndromes associated with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:1628–34.CrossRefGoogle Scholar
  10. 10.
    Miller TL, Orav EJ, Colan SD, et al. Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus. Am J Clin Nutr. 1997;66:660–4.CrossRefGoogle Scholar
  11. 11.
    Yilmaz O, Olgun H, Ciftel M, et al. Dilated cardiomyopathy secondary to rickets-related hypocalcaemia: eight case reports and a review of the literature. Cardiol Young. 2015;25:261–6.CrossRefGoogle Scholar
  12. 12.
    Sanyal D, Raychaudhuri M. Infants with dilated cardiomyopathy and hypocalcemia. Ind J Endocrinol Metabolism. 2013;17:S221–S3.CrossRefGoogle Scholar
  13. 13.
    Kirk R, Dipchand AI, Rosenthal DN, et al. The International Society for Heart and Lung Transplantation guidelines for the management of pediatric heart failure: executive summary. J Heart Lung Transplant. 2014;33:888–909.CrossRefGoogle Scholar
  14. 14.
    Alabed S, Sabouni A, Al Dakhoul S, Bdaiwi Y, Frobel-Mercier AK. Beta-blockers for congestive heart failure in children. Cochrane Database Syst Rev. 2016;1:CD007037.Google Scholar
  15. 15.
    Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015;37(1):67–119.CrossRefGoogle Scholar
  16. 16.
    Marecki JC, Cool CD, Parr JE, Beckey VE, Luciw PA, Tarantal AF, Carville A, Shannon RP, Cota-Gomez A, Tuder RM, Voelkel NF, Flores SC. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med. 2006;174:437–45.  https://doi.org/10.1164/rccm.200601-005OC.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132(21):2037–99.CrossRefGoogle Scholar
  18. 18.
    Montani D, Savale L, Natali D, Jaıs X, Herve P, Garcia G, Humbert M, Simonneau G, Sitbon O. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010;31:1898–907.CrossRefGoogle Scholar
  19. 19.
    Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003;37:292–8.CrossRefGoogle Scholar
  20. 20.
    Mikhail IJ, Purdy JB, Dimock DS, et al. High rate of coronary artery abnormalities in adolescents and young adults infected with human immunodeficiency virus early in life. Pediatr Infect Dis J. 2011;30:710–2.CrossRefGoogle Scholar
  21. 21.
    Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol. 2013;61(5):511–23.CrossRefGoogle Scholar
  22. 22.
    Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. https://aidsinfo.nih.gov/guidelines/htmltables/2/6152. Accessed 14 Mar 2019.
  23. 23.
    Castillo R, Pedalino RP, El-Sherif N, Turitto G. Efavirenz-associated QT prolongation and torsade de pointes arrhythmia. Ann Pharmacother. 2002;36(6):1006–8.CrossRefGoogle Scholar
  24. 24.
    Hunt K, Hughes CA, Hills-Nieminen C. Protease inhibitor-associated QT interval prolongation. Ann Pharmacother. 2011;45(12):1544–50.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Nelson R Mandela School of MedicineUKZNDurbanSouth Africa

Personalised recommendations